MiNK Therapeutics (INKT) reports Q2 2026 results; Phase 2 agenT-797 observations
MiNK Therapeutics (INKT) reports second-quarter 2026 financial results and observations from a randomized Phase 2 trial of agenT-797 in acute lung injury.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.